Clinical Trials Directory

Trials / Unknown

UnknownNCT02161315

Steroid Aromatase Inhibitors Versus Progestogens for nSAID-resistanced Late Stage Breast Cancer

A Randomized Study of Steroid Aromatase Inhibitors Versus Progestogens for Non-Steroid Aromatase Inhibitor-resistanced Late Stage Breast Cancer

Status
Unknown
Phase
Study type
Observational
Enrollment
80 (estimated)
Sponsor
Tianjin Medical University Cancer Institute and Hospital · Academic / Other
Sex
Female
Age
Healthy volunteers
Not accepted

Summary

Steroid Aromatase Inhibitors and Non-Steroid Aromatase Inhibitors in Late Stage Breast Cancer is the recommended scheme in National Comprehensive Cancer Network (NCCN) guideline. In the past controlled clinical trials with small sample.

Detailed description

A Randomized Study of Steroid Aromatase Inhibitors Versus Progestogens for Non-Steroid Aromatase Inhibitor-resistanced Late Stage Breast Cancer.The primary endpoints of the study is progression free survival (PFS). The secondary endpoints are overall response rate (ORR), overall survival (OS) and safety.

Conditions

Timeline

Start date
2014-04-01
Primary completion
2016-11-01
Completion
2016-12-01
First posted
2014-06-11
Last updated
2015-12-22

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT02161315. Inclusion in this directory is not an endorsement.